ABSTRACT
The use of herbarium mixture has been empirical, and the properties are not yet known. The aim of this study was to evaluate the effect of oral administration of herbarium mixture (Guazuma ulmifolia [G. ulmifolia]/Tecoma stans [T. stans]) on metabolic profile in patients with type 2 diabetes mellitus (T2DM). A randomized, double-blind, placebo-controlled, clinical trial was carried out in 40 patients with T2DM. They were between 40 and 65 years of age, with body mass index (BMI) between 25.0 and 34.9 kg/m2 and HbA1c >7.0%. BMI, waist circumference, fasting glucose, HbA1c, lipids, kidney, and liver function were measured. The patients were randomly assigned to receive the herbarium mixture (G. ulmifolia/T. stans) 400 mg before each meal, or placebo for 90 days. Herbarium mixture group showed decreased waist circumference (99 ± 14 vs. 98 ± 15 cm; P = .019), fasting glucose (12.0 ± 5.7 vs. 10.3 ± 5.1 mM; P = .019), and HbA1c (9.9% ± 2.7% vs. 8.9% ± 2.5%, P = .002). In conclusion, the administration of herbarium mixture (G. ulmifolia/T. stans) improved the glycemic profile in patients with T2DM. ClinicalTrial registration: NCT03313856 ClinicalTrials.gov.
Subject(s)
Bignoniaceae , Diabetes Mellitus, Type 2 , Bignoniaceae/metabolism , Blood Glucose , Diabetes Mellitus, Type 2/drug therapy , Double-Blind Method , Glycated Hemoglobin/metabolism , Humans , Hypoglycemic Agents , MetabolomeABSTRACT
Se confirma la importante actividad terapéutica de 13.cRA y del IFNÓ-2a en el carcinoma de células escamosas del cervix sin tratamiento previo. Un resultado inesperado fue la toxicidad temprana de los agentes biológicos sobre la mucosa del colon cuando se combinan con radioterapia
Subject(s)
Adult , Humans , Female , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Endometrioid , Drug Tolerance/radiation effects , Interferon-alpha/administration & dosage , Interferon-alpha/therapeutic use , Isotretinoin/administration & dosage , Isotretinoin/therapeutic use , Retinoids/administration & dosage , Retinoids/therapeutic use , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapyABSTRACT
El acido retinoico y el interferón alfa tienen actividad limitada en el tratamiento de cáncer avanzado. La información obtenida de los cultivos celulares indican que, en combinación, estos agentes tienen incremento de la actividad biológica modulando el crecimiento y la diferenciación en un número de tipos celulares malignos. Trabajos clínicos recientes sobre el tratamiento de algunos carcinomas avanzados de células escamosas informan actividad terapéutica con este régimen. Este artículo revisa los datos preclínicos obtenidos al evaluar el ácido retinoico en combinación con interferones